FDA Selects Four Digital Health Companies For TEMPO Pilot; Two Focus On Behavioral Health

The U.S. Food and Drug Administration (FDA) selected four health technology companies for its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot in July and August 2026, including two offering technologies for behavioral health treatment. SonderMind, Inc. and Limbic, Inc. are offering behavioral health technologies, while Cadence Solutions, Inc. is offering a digital tool for hypertension management, and Dexcom, Inc. is offering a program focused on blood glucose and metabolic health. The four companies are the participants selected to date, and the FDA intends to add participants as additional manufacturers are selected.

The manufacturers intend for their technologies to be . . .